Clinical Trials

Breast Carcinoma In Situ

NCT04852887 2026-03-03

DEBRA

1,670 enrolled

Breast Neoplasms

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT07190443 2025-09-29

AURA

290 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04134598 2025-08-29

EUROPA

926 enrolled

Breast Neoplasms

NCT03011684 2025-05-08

TALES

309 enrolled

Breast Neoplasms, Infertility

NCT00949598 2025-02-13

Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer

177 enrolled

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT01357772 2023-07-17

TAM-01

500 enrolled

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Neoplasm Recurrence, Local

NCT01579734 2023-06-28

HOT

1,884 enrolled

Breast Neoplasms

NCT00412022 2023-03-24

HOBOE

1,294 enrolled

Breast Neoplasms

NCT02914158 2023-01-17

ASPAIT

680 enrolled

Breast Neoplasms

NCT02062489 2022-04-27

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

688 enrolled

Breast Neoplasms

NCT05016349 2021-08-23

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

160 enrolled

Breast Cancer Female

NCT01950182 2020-07-15

SYSUCC-002

392 enrolled

Breast Neoplasms

NCT01758146 2020-03-04

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

412 enrolled

BreastOther

Breast Neoplasms, Obesity

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

3,697 enrolled

Breast Neoplasms

NCT04046159 2019-08-06

Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

810 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT03137368 2018-10-31

STEP

300 enrolled

Breast Neoplasms

NCT01638247 2018-09-19

MALE

56 enrolled

Breast Neoplasms, Male

NCT00687102 2018-09-12

Co-STAR

1,498 enrolled 13 charts

Breast Neoplasms

NCT03351062 2017-11-22

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

844 enrolled

Breast Neoplasms

NCT00293540 2016-07-27

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

249 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00053339 2016-07-12

Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

Phase 3 Withdrawn

Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

600 enrolled

Breast Neoplasms

NCT00201851 2015-04-29

Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

740 enrolled 14 charts

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT01622361 2013-09-30

NEST

290 enrolled

Breast Neoplasms

NCT00003972 2010-04-02

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

280 enrolled

Breast Neoplasms

NCT00912548 2009-06-16

ASTRRA

1,234 enrolled

Breast Neoplasms

NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

913 enrolled